Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas

Rationale: Mutations in KIT, a major cancer driver gene, are now considered as important drug targets for the treatment of melanomas arising from mucosal and acral tissues and from chronically sun-damaged sites. At present, imatinib is the only targeted drug for KIT-mutation-bearing melanomas that i...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yong, Gu, Ziyue, Wu, Jing, Huang, Xiaojuan, Zhou, Rong, Shi, Chaoji, Tao, Wenjie, Wang, Lizhen, Wang, Yanan, Zhou, Guoyu, Li, Jiang, Zhang, Zhiyuan, Sun, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485277/
https://www.ncbi.nlm.nih.gov/pubmed/31037149
http://dx.doi.org/10.7150/thno.30890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485277/
https://www.ncbi.nlm.nih.gov/pubmed/31037149
http://dx.doi.org/10.7150/thno.30890

Ejemplares similares